The objective of this study was to evaluate the antitumor effect of glibenclamide (Gli) No secondary toxic effect was observed after treatment at any assayed doses.
INTRODUCTION
It is known that breast cancer cell growth is dependent on several hormones such as estrogens, prolactin, progesterone, glucocorticoids, insulin, and growth factors. In earlier publications, Heuson and Legros and others researchers reported the importance of insulin in DNA synthesis of the hormone-dependent mammary carcinomas induced by 7,12-dimethylbenz(a)antracene (DMBA) and classified mammary tumors as dependent or independent to insulin for their growth (1) . These pioneering experiments attributed a crucial role to insulin in the development of mammary tumors. Currently, it is undoubted that insulin, insulin-like growth factors type I (IGF-I) and type II (IGF-II), their corresponding receptors (IGF-IR and IGF-IIR) and binding proteins (IGFBPs) participate in the development of normal and neoplasic mammary tissue (2, 3) . Furthermore, clinical observations indicate that breast cancer patients with non-insulin-dependent diabetes mellitus (NIDDM) showed a better evolution and a longer survival time when were treated with the combination of the antiestrogen tamoxifen (Tam) plus hypoglycemic drugs (4) (5) (6) . The second generation of hypoglycemic sulfonylureas includes glibenclamide (Gli). These drugs cause hypoglycemia by stimulation of insulin release from beta pancreatic cells, interacting with surface receptors of those cells and regulating the levels of glucose in type II diabetes (NIDDM) (7) . Many sulfonylureas showed experimental evidence of antitumor activity (8) (9) (10) and some of these compounds advanced to phase I and II clinical studies, sometimes showing adverse effects (8, 9, 11) .
In our laboratory we characterized an experimental mammary tumor induced by three ip injections of the carcinogen N-nitroso-N-methylurea (NMU) at 50, 80 and 110 days of life in normal (12, 13) and diabetic rats (14, 15) . The objective of the present study was to evaluate the in vivo antitumor action of glibenclamide alone or in combination with Tam on induced mammary tumors in normal and diabetic rats. Therefore, we determined: a) glucose tolerance curves; b) blood insulin levels; c) plasma IGF-I levels; d) pancreatic and tumor histopathology; and e) mammary tumor growth.
MATERIALS AND METHODS

Reagents
NMU, STZ and citrate buffer, pH 4.8, were purchased from Sigma Chemical Co., (St. Louis, Missouri, USA). A blood glucose micromethod (Glucometer Gx, Ames S.A., Argentina) was used to determine glucose levels. The reagents for IGF-I determination by radioimmunoassay (RIA) were purchased from Diagnostic Systems Laboratories Inc. (Texas, USA) and the kit for insulin RIA was from International CIS (France). Glibenclamide was a gift from Raffo Laboratories SA, (Buenos Aires, Argentina). Tamoxifen was a gift from Gador Laboratories SA (Buenos Aires, Argentina).
Animals.
Female Sprague-Dawley rats were randomly separated into batches and housed in stainless steel cages, with water and food ad libitum, temperature of 22-23°C, humidity around 56% and a 12 h light-dark cycle. In all the cases animals were kept at conditions recommended by the Guide for the Care and Use of Laboratory Animals, National Research Council, USA, 1996.
Diabetes induction.
On the second day of life, one-half of the rats were injected sc with 90 mg/kg of STZ in 0.09 M citrate buffer, pH 4.8, as previously described (14, 15) . Tumor induction. Rats, both non-diabetic and diabetic, were injected with three doses of NMU at 50, 80 and 110 days of life as previously described (12) . The developed tumors were measured with a caliper three days a week to control their size and growth.
Glucose Tolerance Test (GTT).
At day 45, rats were subjected to a glucose tolerance test (GTT); after basal blood glucose determination, 2 mg/kg of glucose was injected ip and glucose circulating levels were determined at 30, 60 and 120 min. Animals showing abnormal GTT were selected for diabetic groups.
GTT in rats under Gli treatment. Determination of the effective Gli dose. Doses of Gli capable of normalizing the GTT in diabetic rats were evaluated as we described above. The Gli concentration range was extrapolated from doses used in human diabetic patients (16) .
Four groups of 130 day-old diabetic rats were randomly separated (n = 5). Three groups were treated with Gli (suspended in 50% glycerin) at 0.02, 0.04, or 0.06 mg/day (STZ+Gli 0.02, STZ+Gli 0.04, or STZ+Gli 0.06 mg/day groups, respectively) for twenty days; the fourth group (STZ) was treated with vehicle. Also, five non-diabetic rats without treatment (n = 5) were employed as a control group (Control).
Effects of Gli, Tam and Gli+Tam treatment on tumor growth. Studies of the effects of 0.06 mg/day of Gli on tumor growth in diabetic and non-diabetic rats bearing NMU-induced mammary tumors were performed. Results were compared to those obtained in rats receiving 1 mg/kg/day of treatment with Tam (13, 17) , and the effects of combined Gli+Tam treatment were analyzed; Table 1 summarizes the treatment schedule. The parameters recorded were:
Relative tumor size, calculated as the relationship between tumor size at different times versus the beginning of treatments; Percentage of tumor regression: each tumor was classified as regressing, growing, or stable according to the size in relation to the pre-treatment value.
Tumors were considered regressing when their diameters were 80% lower than the diameter at the beginning of the treatment. Tumor size was determined by measurement of two perpendicular diameters three days a week (12) . Tumor histopathology was determined according to the classification of Russo et al. (18) . Histopathological studies. Histological observations of the pancreas and mammary tumors were performed. Specimens were fixed in 10% formaldehyde and embedded in paraffin.
Slides were stained with haematoxylin-eosin (HE) for microscopic observation. Specimens of pancreas were also fixed in Bouin's solution and embedded in paraffin to evaluate the number and extension of Langerhans islets. Serial sections of the whole pancreas of each rat were examined. Gomori trichromic stained slides were microscopically examined to discriminate between alpha and beta pancreatic cells (19) . Statistical analyses. In each figure and table the respective statistic test used is indicated (20) . Figure 1 describes the results obtained for rats lacking tumors.
RESULTS
Glucose Tolerance Test.
After glucose injection, only the STZ+Gli 0.06 mg/day treated rats had a recovery of glucose levels to values similar of those of non-diabetic animals. The STZ+Gli 0.02 and STZ+Gli 0.04 groups did not change significantly their GTT versus diabetic rats (i.e., the STZ group) (Fig. 1a) . Non-diabetic animals treated with 0.02, 0.04, or 0.06 mg/day of Gli did not change the GTT significantly versus the Control group (data not shown).
Non-diabetic and diabetic rats bearing mammary NMU induced tumors were treated with 0.06 mg/day Gli as described above. Results indicated that NMU injections did not affect GTT. Non-diabetic rats treated with 0.06 mg/day of Gli (NMU+Gli group) showed similar GTT to the NMU group. Also, diabetic rats bearing mammary tumors (STZ+NMU+Gli group) showed a similar GTT to non-diabetic ones (NMU) (Fig. 1b) .
Insulin levels. To determine if the 0.06 mg/day level of Gli elevates the circulating levels of insulin, fast insulin values were determined pre-and post-treatment in rats bearing mammary tumors ( Table 2) . No significant differences in insulin circulating levels between NMU+Gli vs NMU rats were seen. Diabetic rats (STZ+NMU group) showed a non-significant lower insulin value than the NMU treated rats. However, in diabetic rats receiving 0.06 mg/day of Gli (the STZ+NMU+Gli group), the insulin levels were significantly increased vs STZ+NMU values (P<0.05).
tIGF-I circulating levels. Table 2 
Histopathological studies
Pancreas. The pancreas from non-diabetic rats always showed a normal structure with a normal number and size of islets. Alfa cells are located in the periphery of the islets and beta cells are in the center of the islets (Fig. 2a) , according to reported observations (21) . In contrast, all of the diabetic rats showed a pancreas with a low number of islets that were smaller and with scarce beta cells when were compared with normal ones (Fig. 2b) .
Pancreases from non-diabetic and Gli treated rats were of normal size with hypersecreting 8 alpha cells (Fig. 2c) . Pancreases from diabetic rats treated with 0.06 mg/day of Gli, showed smaller and lower numbers of islets than normal pancreases and with scarce beta cells, similarly to that described for diabetic rats. Also, appreciable cytoplasmic depletion in beta cells was observed (Fig. 2d) .
Tumors. All tumors from NMU treated rats were malignant adenocarcinomas with a cribriform, comedo or papillary pattern. Tumors of diabetic rats (STZ+NMU) showed predominantly a benign pattern, as we have previously described (15) . Figure 3 illustrates the hypersecretion observed in the lumen of the mammary tumors of Gli treated rats (Fig. 3a, 3b and 3c). The appearance of these tumors was similar to that from Tam treated rats (Fig. 3d ).
Tumors Gli+Tam treated exhibited similar characteristics (data not shown).
Effects of treatments on tumors of non-diabetic rats.
Tumor growth. Table 3 No significant differences between final mean sizes of tumors regressing with Tam treatment (NMU+Tam(r)) versus those regressing with Gli treatment (NMU+Gli(r)) were found ( Fig. 4b and Fig. 4a ).
Effects of treatments on tumors of diabetic rats.
Tumor growth. In diabetic rats no evidence of spontaneous tumor regression was seen (STZ+NMU group, Fig. 4c ). When diabetic rats were treated with 0.06 mg/day of Gli (STZ+NMU+Gli), no response was observed (Table 4) Relative tumor size. Figure 4c illustrates the mean size of Gli-treated tumors. The tumors from diabetic rats that regressed with Tam treatment (i.e., the STZ+NMU+Tam group) reached 10 to 55% of the size at the beginning of the treatment (Fig 4d) .
Effect of combined Gli+Tam treatments in non-diabetic and diabetic rats.
Tumor growth and relative tumor size. When the combination treatments were administered, 100% of the tumors of non-diabetic rats were responsive ( Table 3) , showing that Gli potentiate the effect of Tam. In the case of diabetic rats (Table 4) , the combined treatment (89% of regression) did not show significant differences with Tam alone treatment.
Apoptosis.
The effecs of Gli, Tam and Gli+Tam treatment on apoptosis, mitosis and necrosis in mammary tumors in non-diabetic rats were also studied. Table 5 (Table 5 and Fig. 5 ).
Finally, no evidence of toxic side effects were observed during the observation period. Also, studies in progress in our laboratory show that Gli treated rats have a longer survival time than non-treated ones.
DISCUSSION
It is known that the streptozotocin injection at the second day of life of rats provokes the destruction of pancreatic beta cells and the development of a diabetic syndrome (22) .
However, the survival time and the metabolic conditions of these animals are different to the experiments described in this paper. The first set of in vivo experiments showed that only 0.06 mg/day of glibenclamide restored GTT in diabetic rats and did not produce a significant increase in plasma insulin levels in non-diabetic rats. This finding may be explained by the In all the studies, two-way ANOVA and Tukey post-test NMU, N-Nitroso-N-methylurea; Gli, glibenclamide; Tam, tamoxifen.
